An upper endoscopic approach called 3D endoscopy enables better tissue sampling from the oesophagus than does traditional endoscopy.
A specialised brush only samples the layer of the oesophagus where cancer cells originate while covering a larger region.
Simple surgical procedures including finding, sampling, or removing tumours from the digestive system and lungs are carried out using endoscopes that are specially developed for the job.
locating and eliminating foreign items from the digestive and pulmonary systems. obtaining tiny tissue samples for a biopsy in order to get a diagnosis.
The bronchoscope, a flexible tube for inspecting the bronchial tubes, and the endoscope, a flexible tube for inspecting the oesophagus, stomach, and duodenum.
This treatment is quite safe as long as the equipment is adequately cleaned, or reprocessed, before each procedure to remove any chance of infection spreading from one patient to another.
The Global 3D endoscopy system market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.
Olympus Launches VISERA ELITE III Surgical Visualization Platform.An innovative and open solution bringing together multiple observation modes for future-proof endoscopic surgery.
The release of its newest surgical visualisation platform, VISERA ELITE III, which caters to the requirements of healthcare professionals (HCPs) for endoscopic operations across many medical disciplines.
A single system, VISERA ELITE III, supports a variety of imaging capabilities that enable minimally invasive procedures such laparoscopic cholecystectomy and laparoscopic colectomy.
Future software updates will enhance surgical imaging technology and enable custom setups that simplify the smooth integration of multiple surgical applications, lowering investment costs.
The VISERA ELITE III system combines the 4K imaging function from the VISERA 4K UHD system with the 3D and infrared imaging features from the VISERA ELITE II system.
It also supports NBI2, an original observation mode created by Olympus, and fluorescence-guided surgery. The all-in-one system promotes standardisation and boosts productivity in the operating room by giving surgeons a variety of viewing modes.
On VISERA ELITE III, users may also create personalised departmental profiles for a variety of medical specialties, including general surgery, urology, gynaecology, ENT surgery, and more. The platform works with VISERA ELITE II endoscopes that are currently in use.
As needed, the platform enables for software upgrades to provide additional surgical imaging functionalities. Switching full surgical visualisation systems to access the most up-to-date technology is no longer required, which not only establishes a new benchmark and gives a high degree of flexibility, but also makes VISERA ELITE III a future-proof investment.
The VISERA ELITE III system has a focus change mode for 4K surgical observation, as well as an EDOF (Extended Depth of Field) capability for precise endoscopic observations via continuous broad focus and seamless magnification.
It also has C-AF (Continuous AutoFocus) capabilities, which continuously adjusts focus based on the movement of the camera head and endoscope.
This allows for clearer picture acquisition, both up close and at a distance, so that HCPs are less stressed during surgery and can focus on the patient and the procedure’s success.
VISERA ELITE III combines Sony Corporation’s cutting-edge digital imaging technologies with Olympus’ expertise and experience in medical product development accumulated over decades as a leading endoscope manufacturer, and addresses the growing needs of hospitals as identified through extensive customer exchange.
Sony Olympus Medical Solutions, a joint venture of Sony and Olympus, optimised each technology and image processing function specifically for medical applications in order to create the most advanced, open, and versatile surgical visualisation platform Olympus has ever brought to market with VISERA ELITE III.
© Copyright 2017-2023. Mobility Foresights. All Rights Reserved.